LAUSR

Thyroid cancer is the most frequent endocrine tumor. However, in locally advanced or metastatic disease we have only two types of treatment at our disposal: radioactive iodine (RAI) when the disease is RAI‐sensitive and multikinase inhibitors (MKIs), lenvatinib and sorafenib, when the disease becomes RAI‐refractory (RR). This review revisits the published data on the potential combination of MKIs/lenvatinib with RAI in RR‐differentiated thyroid cancer and evaluates some special situations where this combination may be of particular interest. The combination of MKIs/lenvatinib with RAI could, at least hypothetically, improve the efficacy seen in both treatments alone via a synergistic effect and with a lower rate of toxicity rates. Early preclinical data support this notion, while its generalized use awaits the results of ongoing clinical trials.